IMV EBIT per osake

Mitä IMV tekee? IMV, Inc. develops novel cancer immunotherapies and vaccines, focusing on DPX-based cancer vaccines like maveropepimut-S (MVP-S). MVP-S targets survivin, a cancer antigen overexpressed in advanced cancers, and includes an innate immune activator and CD4 T cell helper peptide. It is administered every two months in low doses, driving persistent immune attacks on tumor cells. The company evaluates MVP-S in Phase IIB trials for advanced r/r Diffuse Large B Cell Lymphoma and platinum resistant ovarian cancer. IMV, Inc. generates revenue through clinical development and potential future commercialization of its DPX platform-based therapies. The primary therapeutic candidate, MVP-S, is being tested in Phase IIB trials for specific cancer types, with the company aiming to secure regulatory approvals for these indications. The firm's focus on DPX technology positions it to develop additional cancer vaccines targeting various antigens. The company's target segments include patients with advanced solid or hematological cancers, particularly those with r/r Diffuse Large B Cell Lymphoma and platinum resistant ovarian cancer. These patient groups represent high unmet medical needs, aligning with IMV's focus on developing therapies for difficult-to-treat cancers. IMV's business model relies on advancing clinical trials to demonstrate efficacy and safety, paving the way for potential partnerships or direct sales once approved. IMV on yksi Eurpooliin suosituimmista yhtiöistä.